Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Shares Sold by Fox Run Management L.L.C.

Fox Run Management L.L.C. trimmed its holdings in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) by 6.6% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 52,342 shares of the biotechnology company’s stock after selling 3,684 shares during the quarter. Fox Run Management L.L.C.’s holdings in Arrowhead Pharmaceuticals were worth $984,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. R Squared Ltd acquired a new position in Arrowhead Pharmaceuticals in the fourth quarter valued at approximately $38,000. Van ECK Associates Corp boosted its holdings in Arrowhead Pharmaceuticals by 72.3% in the fourth quarter. Van ECK Associates Corp now owns 2,978 shares of the biotechnology company’s stock valued at $56,000 after purchasing an additional 1,250 shares in the last quarter. KBC Group NV boosted its holdings in Arrowhead Pharmaceuticals by 45.9% in the fourth quarter. KBC Group NV now owns 5,224 shares of the biotechnology company’s stock valued at $98,000 after purchasing an additional 1,644 shares in the last quarter. Quantbot Technologies LP acquired a new position in Arrowhead Pharmaceuticals in the third quarter valued at approximately $149,000. Finally, Envestnet Portfolio Solutions Inc. acquired a new stake in shares of Arrowhead Pharmaceuticals in the fourth quarter valued at approximately $190,000. 62.61% of the stock is owned by institutional investors and hedge funds.

Arrowhead Pharmaceuticals Trading Down 2.1 %

NASDAQ ARWR opened at $14.80 on Friday. The stock has a market capitalization of $2.03 billion, a P/E ratio of -2.86 and a beta of 0.92. Arrowhead Pharmaceuticals, Inc. has a 52-week low of $14.23 and a 52-week high of $30.41. The firm has a 50-day moving average price of $18.58 and a 200 day moving average price of $19.90. The company has a quick ratio of 6.09, a current ratio of 6.09 and a debt-to-equity ratio of 7.27.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last posted its quarterly earnings results on Monday, February 10th. The biotechnology company reported ($1.39) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.42) by ($0.97). Equities research analysts expect that Arrowhead Pharmaceuticals, Inc. will post -2.42 EPS for the current year.

Insider Buying and Selling

In other Arrowhead Pharmaceuticals news, CEO Christopher Richard Anzalone sold 51,425 shares of the company’s stock in a transaction dated Thursday, March 13th. The shares were sold at an average price of $15.07, for a total transaction of $774,974.75. Following the transaction, the chief executive officer now directly owns 4,062,377 shares in the company, valued at approximately $61,220,021.39. This represents a 1.25 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Adeoye Y. Olukotun sold 2,850 shares of the company’s stock in a transaction dated Friday, December 27th. The stock was sold at an average price of $20.00, for a total transaction of $57,000.00. Following the transaction, the director now owns 36,740 shares in the company, valued at $734,800. The trade was a 7.20 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 301,730 shares of company stock valued at $5,352,844 over the last ninety days. Corporate insiders own 4.30% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have recently commented on ARWR shares. Citigroup cut their target price on shares of Arrowhead Pharmaceuticals from $27.00 to $26.00 and set a “neutral” rating on the stock in a report on Wednesday, November 27th. HC Wainwright restated a “buy” rating and issued a $80.00 price objective on shares of Arrowhead Pharmaceuticals in a research note on Wednesday, February 12th. StockNews.com raised shares of Arrowhead Pharmaceuticals to a “sell” rating in a report on Friday, December 20th. Chardan Capital reaffirmed a “buy” rating and issued a $60.00 target price on shares of Arrowhead Pharmaceuticals in a report on Tuesday, February 11th. Finally, Piper Sandler reduced their target price on shares of Arrowhead Pharmaceuticals from $62.00 to $45.00 and set an “overweight” rating for the company in a report on Wednesday, November 27th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and six have given a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $41.44.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.